- Home
- DNLI vs WVE Comparison
DNLI vs WVE Comparison
Compare DNLI & WVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DNLI
- WVE
- Stock Information
- Founded
- DNLI 2013
- WVE 2012
- Country
- DNLI United States
- WVE Singapore
- Employees
- DNLI N/A
- WVE N/A
- Industry
- DNLI Biotechnology: Biological Products (No Diagnostic Substances)
- WVE Biotechnology: Pharmaceutical Preparations
- Sector
- DNLI Health Care
- WVE Health Care
- Exchange
- DNLI Nasdaq
- WVE Nasdaq
- Market Cap
- DNLI 2.1B
- WVE 1.7B
- IPO Year
- DNLI 2017
- WVE 2015
- Fundamental
- Price
- DNLI $12.29
- WVE $7.74
- Analyst Decision
- DNLI Strong Buy
- WVE Strong Buy
- Analyst Count
- DNLI 16
- WVE 11
- Target Price
- DNLI $37.57
- WVE $22.00
- AVG Volume (30 Days)
- DNLI 1.3M
- WVE 1.3M
- Earning Date
- DNLI 05-06-2025
- WVE 03-04-2025
- Dividend Yield
- DNLI N/A
- WVE N/A
- EPS Growth
- DNLI N/A
- WVE N/A
- EPS
- DNLI N/A
- WVE N/A
- Revenue
- DNLI N/A
- WVE $108,302,000.00
- Revenue This Year
- DNLI N/A
- WVE N/A
- Revenue Next Year
- DNLI $373.37
- WVE $33.28
- P/E Ratio
- DNLI N/A
- WVE N/A
- Revenue Growth
- DNLI N/A
- WVE N/A
- 52 Week Low
- DNLI $12.05
- WVE $4.25
- 52 Week High
- DNLI $33.33
- WVE $16.74
- Technical
- Relative Strength Index (RSI)
- DNLI 29.24
- WVE 31.52
- Support Level
- DNLI $13.67
- WVE $9.43
- Resistance Level
- DNLI $14.84
- WVE $10.91
- Average True Range (ATR)
- DNLI 0.81
- WVE 0.63
- MACD
- DNLI 0.03
- WVE -0.18
- Stochastic Oscillator
- DNLI 5.84
- WVE 3.21
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.
About WVE Wave Life Sciences Ltd.
WAVE Life Sciences Ltd is unlocking the broad potential of RNA medicines also known as oligonucleotides, it targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISMTM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, splicing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.